As previously reported, BofA/Merrill upgraded AmerisourceBergen to Buy from Neutral and raised its price target to $94 from $85. Analyst Steven Valiquette said there is "tangible" evidence that brand inflation has improved following the election with more drugs having increased prices through mid-January 2017, 115 out of the top 500, versus 112 out of the top 500, in all of January 2016. The analyst believes AmerisourceBergen earnings are positioned to come in at the higher end given better trends and raised his 2017 earnings estimate to $5.85 from $5.77, versus consensus of $5.75.